Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey

BACKGROUND: The anti-CD38 monoclonal antibody daratumumab is approved as a single agent for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) who received at least three prior lines of therapy, including proteasome inhibitor and immunomodulatory agent. A retrospective multic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Markovic, Uros, Romano, Alessandra, Del Fabro, Vittorio, Bellofiore, Claudia, Bulla, Anna, Parisi, Marina Silvia, Leotta, Salvatore, Gentile, Massimo, Cangialosi, Clotilde, Vincelli, Iolanda, Mineo, Giuseppe, Rossi, Marco, Poidomani, Massimo, Uccello, Giuseppina, Maugeri, Cinzia, Mannina, Donato, Innao, Vanessa, Di Raimondo, Francesco, Conticello, Concetta
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7982826/
https://ncbi.nlm.nih.gov/pubmed/33763359
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.624405
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados